Acquisitions, Proposed Development Activities, Voting Rights, and Share Capital Updates - Analyst Notes on Morgan Advanced Materials, Unite, Dechra Pharmaceuticals, Dunelm and IG

LONDON, June 11, 2014 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Earnings Review released its analysts' notes regarding Morgan Advanced Materials Plc (LON: MAGM), Unite Group (LON: UTG), Dechra Pharmaceuticals Plc (LON: DPH), Dunelm Group Plc (LON: DNLM) and IG Group (LON: IGG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://earnings-review.com/3613-100free.

Morgan Advanced Materials Plc Analyst Notes

On June 9, 2014, Morgan Deutschland Holding GmbH, a wholly owned subsidiary of Morgan Advanced Materials Plc (Morgan Advanced Materials) announced the acquisition of leading insulation manufacturer Porextherm Dämmstoffe GmbH (Porextherm), adding to its existing portfolio of thermal insulation products and solutions. Morgan Advanced Materials informed that the completion of the acquisition is subject to customary closing conditions, including approval from the German competition authority. Mark Robertshaw, CEO Morgan Advanced Materials, commented, "The addition of Porextherm to the Morgan Group enhances our existing portfolio of high-performance insulating systems, and also gives us the chance to share knowledge and processes which will lead to future product development. In line with our strategic priorities, the acquisition brings with it the opportunity to explore new markets and expand our range to benefit both new and existing customers". Established in 1989, Porextherm clocked sales of approximately €24 million in 2013. The full analyst notes on Morgan Advanced Materials are available to download free of charge at:

http://earnings-review.com/3613-MAGM-11Jun2014.pdf

Unite Group Analyst Notes

On May 30, 2014, Unite Group (Unite) reported that it has agreed to acquire and redevelop a 0.77 acre site in Portsmouth which, as per the planning, is expected to provide around 830 new beds and will help address the shortage of purpose built student accommodation in the city. The Company expects redevelopment activity to be completed in time for the 2016/17 academic year and that returns will be in line with Unite's targets for regional development. According to the Company, the acquisition, which is subject to planning and funding agreements, will further consolidate Unite's position as the leading student accommodation provider in Portsmouth. Richard Simpson, Managing Director of Property for Unite Students, commented, "The new development will incorporate Unite's new look and feel which includes a series of innovations and improvements that will create a genuine home for students that help them succeed at university." The full analyst notes on Unite are available to download free of charge at:

http://earnings-review.com/3613-UTG-11Jun2014.pdf

Dechra Pharmaceuticals Plc Analyst Notes

On May 30, 2014, Dechra Pharmaceuticals Plc (Dechra Pharmaceuticals) notified that the Company's issued share capital consists of 87.7 million ordinary shares with a nominal value of One pence each (Ordinary Shares), with voting rights. The Company does not hold any Ordinary Shares in Treasury. Hence, the total number of Ordinary Shares with voting rights is 87.7 million. Dechra Pharmaceuticals is an international specialist veterinary pharmaceuticals and relates products business. The full analyst notes on Dechra Pharmaceuticals are available to download free of charge at:

http://earnings-review.com/3613-DPH-11Jun2014.pdf

Dunelm Group Plc Analyst Notes

On June 2, 2014, Dunelm Group Plc (Dunelm) notified that the Company's issued ordinary share capital consists of 202.8 million ordinary shares with a nominal value of One pence each (Ordinary Shares), out of which a total of 941,985 shares are held in treasury. Therefore the total number of ordinary shares with voting rights in the Company is 201.9 million ordinary shares. This number (201.9 million) may be used by shareholders in the Company as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change in their interest in, the ordinary share capital of the Company under the Disclosure and Transparency Rules. The full analyst notes on Dunelm are available to download free of charge at:

http://earnings-review.com/3613-DNLM-11Jun2014.pdf

IG Group Analyst Notes

On June 2, 2014, IG Group (IG) informed that there has been no change in the Company's issued share capital since the Total Voting Rights notification as at April 30, 2014. The Company's issued share capital as at May 31, 2014 comprises of 365.7 million ordinary shares of 0.005 pence each, with voting rights. IG stated that it does not hold any of the ordinary shares in Treasury. The full analyst notes on IG are available to download free of charge at:

http://earnings-review.com/3613-IGG-11Jun2014.pdf

===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] earnings-review.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] earnings-review.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] earnings-review.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Earnings Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Earnings Review in this article or report according to the procedures outlined by Earnings Review. Earnings Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Earnings Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Earnings Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Earnings Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Earnings Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Earnings Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.